What is Sales and Marketing Strategy of Shenzhen Hepalink Pharmaceutical Group Co. Company?

The company builds its brand primarily through the inherent quality of its pharmaceutical products. This approach aims to establish trust and recognition in a competitive market.

Rather than engaging in price wars, Hepalink maintains a consistent pricing system. This reflects confidence in their product value and aims for sustainable market positioning.

In its API business, despite a decline in average export unit prices in 2024 due to lower raw material costs, Hepalink upheld its pricing. This strategy resulted in sales volume growth, with average selling prices remaining significantly above the Chinese export average.

Within the pharmaceutical sector, marketing efforts heavily involve direct engagement with healthcare professionals (HCPs). Demonstrating product efficacy through robust clinical data is paramount.

The company leverages its established domestic and international marketing networks for global expansion. Its heparin finished dose business shows a positive trend with continued sales growth across Europe, the United States, China, and other regions.

While specific digital tactics are not detailed, the pharmaceutical industry's trend towards digital engagement is notable. By 2025, ethical, transparent, and data-driven approaches are expected to dominate, with social media and patient communities playing larger roles.

Hepalink's products are recognized as market leaders within Europe, demonstrating significant brand penetration and acceptance in this key region.

The inclusion of Hepalink's products in national insurance programs in the UK, Switzerland, and 13 EU member countries highlights strong market validation and trust.

The company actively pursues market share growth in crucial regions like Europe, the United States, and China, reflecting a deliberate global marketing strategy.

Hepalink's market approach prioritizes brand building and product quality, a strategic response to competitive threats and evolving market conditions.

A gross profit margin of approximately 33.1% in 2024 and a net profit of approximately RMB624.9 million underscore the company's financial health and market competitiveness.

The company's strategic expansion into innovative drugs and biosimilars demonstrates a forward-looking approach to its product portfolio and market positioning.

The company's deliberate strategy to avoid price wars and instead focus on enhancing product competitiveness is a sustained marketing campaign. This approach aims to consolidate market share by emphasizing value and quality, aligning with its overall Mission, Vision & Core Values of Shenzhen Hepalink Pharmaceutical Group Co.

Within its CDMO business, Hepalink's sales and marketing efforts are focused on deepening cooperative relationships with existing clients. This client-centric approach is vital for retaining business and fostering long-term partnerships in the biologics sector.

Concurrently, the company is actively engaged in a campaign to acquire new customers for its CDMO services. This expansion of its client portfolio is a key driver for growth in the competitive biologics manufacturing market.

The successful VBP bid in China exemplifies a strategic 'campaign' to leverage centralized procurement mechanisms. This allows Hepalink to achieve greater market penetration and drive significant profit growth through increased sales volumes.

The overarching sales and marketing strategy for finished dose products is centered on enhancing global market share. This is achieved through consistent market expansion and a focus on product quality and accessibility.

Hepalink's approach to its CDMO business involves targeted business development and relationship marketing. This strategy aims to expand its service offerings and client base within the large molecule biologics sector.